IN THE CLAIMS

1. (currently amended)   A method for treating <u>cutaneous</u> inflammation, the method comprising:

administering an effective amount of an inhibitor of integrin linked kinase (ILK) wherein said ILK inhibitor is a small organic molecule<u> that blocks ILK activity</u>.

2. (original) The method according to Claim 1, wherein said inflammation is associated with autoimmune disease.

3. (canceled)

4. (currently amended)   The method according to Claim 1, wherein said inflammation is associated with a disease selected from the group consisting of psoriasis, ~~rheumatoid arthritis,~~ ~~multiple sclerosis,~~ scleroderma, systemic lupus erythematosus, ~~Sjögren's syndrome~~, atopic dermatitis, ~~asthma~~, and allergy.

5. (original) The method according to Claim 1, wherein said inflammation is associated with psoriasis.

6. (original) The method according to Claim 5, further comprising the step of administering a second therapy for psoriasis.

7. (original) The method according to Claim 3, wherein second therapy is selected from the group consisting of systemic therapy, ultraviolet light therapy, and topical therapy.

8. (original) The method according to Claim 3, wherein said second therapy is selected from the group consisting of antibiotics, antimicrobials, cyclosporine, methotrexate, hydroxyurea, NSAIDs, sulfasalazine, 6-thioguanine, acitretin, etretinate, isotretinoin; UVB phototherapy, photochemotherapy (PUVA), anthralin, calcipotriene, coal tar, corticosteroids, and tazarotene.

9. (original) The method according to Claim 1, wherein said ILK inhibitor is administered systemically.

2

10. (original) The method according to Claim 1, wherein said ILK inhibitor is administered dermally.

11-12 (canceled)

13. (withdrawn) The method according to Claim 1, wherein said ILK inhibitor is a small organic molecule that blocks ILK catalytic or binding activity.

14. (withdrawn) The method according to Claim 1, wherein said ILK inhibitor is an agent that affects ILK activity through direct or indirect modulation of $[PtdIns(3,4,5)P_3]$ levels.